Cefodizime in complicated urinary tract infections

Masaya Tsugawa; Daisuke Yamada; Yoshitsugu Nasu; Mikio Kishi; Akihiro Mizuno; Hiromi Kumon; Hiroyuki Ohmori; Katsuichi Nanba; Yasuhiro Katayama; Katsuyoshi Kondo; Teruaki Akaeda; Hitoshi Takamoto

doi:10.11250/chemotherapy1953.36.Supplement5_677

Cefodizime in complicated urinary tract infections

Masaya Tsugawa, Daisuke Yamada, Yoshitsugu Nasu, Mikio Kishi, Akihiro Mizuno, Hiromi Kumon, Hiroyuki Ohmori, Katsuichi Nanba, Yasuhiro Katayama, Katsuyoshi Kondo, Teruaki Akaeda, Hitoshi Takamoto

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

We studied the antibacterial activity and clinical efficacy of cefodizime, a new cephem antibiotic. 1. The antibacterial activity of cefodizime was weak against P. aeruginosa, but excellent against E. coli, K. pnessmoniae, P. mirabilis and S. marcescens. Against E. faecalis and S. marcescens the drug was superior to CPZ and LMOX, but against P. aeruginosa it was inferior to CTX, CPZ and LMOX. 2. Thirty-one patients with complicated urinary tract infection were treated with cefodizime. According to the criteria of the UTI Committee, the overall clinical efficacy rate was 70.4%(19/27). 3. As for side-effects, diarrhea was observed in 1 patient (3%), and abnormal laboratory findings were observed in 3 patients, showing transient elevation of GOT/GPT or anemia.

Original language	English
Pages (from-to)	677-690
Number of pages	14
Journal	CHEMOTHERAPY
Volume	36
DOIs	https://doi.org/10.11250/chemotherapy1953.36.Supplement5_677
Publication status	Published - Jan 1 1988

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.36.Supplement5_677

Cite this

@article{d8b66376a0a24b118a64f39a9ae59081,

title = "Cefodizime in complicated urinary tract infections",

abstract = "We studied the antibacterial activity and clinical efficacy of cefodizime, a new cephem antibiotic. 1. The antibacterial activity of cefodizime was weak against P. aeruginosa, but excellent against E. coli, K. pnessmoniae, P. mirabilis and S. marcescens. Against E. faecalis and S. marcescens the drug was superior to CPZ and LMOX, but against P. aeruginosa it was inferior to CTX, CPZ and LMOX. 2. Thirty-one patients with complicated urinary tract infection were treated with cefodizime. According to the criteria of the UTI Committee, the overall clinical efficacy rate was 70.4%(19/27). 3. As for side-effects, diarrhea was observed in 1 patient (3%), and abnormal laboratory findings were observed in 3 patients, showing transient elevation of GOT/GPT or anemia.",

author = "Masaya Tsugawa and Daisuke Yamada and Yoshitsugu Nasu and Mikio Kishi and Akihiro Mizuno and Hiromi Kumon and Hiroyuki Ohmori and Katsuichi Nanba and Yasuhiro Katayama and Katsuyoshi Kondo and Teruaki Akaeda and Hitoshi Takamoto",

year = "1988",

month = jan,

day = "1",

doi = "10.11250/chemotherapy1953.36.Supplement5_677",

language = "English",

volume = "36",

pages = "677--690",

journal = "Chemotherapy",

issn = "0009-3165",

}

TY - JOUR

T1 - Cefodizime in complicated urinary tract infections

AU - Tsugawa, Masaya

AU - Yamada, Daisuke

AU - Nasu, Yoshitsugu

AU - Kishi, Mikio

AU - Mizuno, Akihiro

AU - Kumon, Hiromi

AU - Ohmori, Hiroyuki

AU - Nanba, Katsuichi

AU - Katayama, Yasuhiro

AU - Kondo, Katsuyoshi

AU - Akaeda, Teruaki

AU - Takamoto, Hitoshi

PY - 1988/1/1

Y1 - 1988/1/1

N2 - We studied the antibacterial activity and clinical efficacy of cefodizime, a new cephem antibiotic. 1. The antibacterial activity of cefodizime was weak against P. aeruginosa, but excellent against E. coli, K. pnessmoniae, P. mirabilis and S. marcescens. Against E. faecalis and S. marcescens the drug was superior to CPZ and LMOX, but against P. aeruginosa it was inferior to CTX, CPZ and LMOX. 2. Thirty-one patients with complicated urinary tract infection were treated with cefodizime. According to the criteria of the UTI Committee, the overall clinical efficacy rate was 70.4%(19/27). 3. As for side-effects, diarrhea was observed in 1 patient (3%), and abnormal laboratory findings were observed in 3 patients, showing transient elevation of GOT/GPT or anemia.

AB - We studied the antibacterial activity and clinical efficacy of cefodizime, a new cephem antibiotic. 1. The antibacterial activity of cefodizime was weak against P. aeruginosa, but excellent against E. coli, K. pnessmoniae, P. mirabilis and S. marcescens. Against E. faecalis and S. marcescens the drug was superior to CPZ and LMOX, but against P. aeruginosa it was inferior to CTX, CPZ and LMOX. 2. Thirty-one patients with complicated urinary tract infection were treated with cefodizime. According to the criteria of the UTI Committee, the overall clinical efficacy rate was 70.4%(19/27). 3. As for side-effects, diarrhea was observed in 1 patient (3%), and abnormal laboratory findings were observed in 3 patients, showing transient elevation of GOT/GPT or anemia.

UR - http://www.scopus.com/inward/record.url?scp=0023696995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023696995&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.36.Supplement5_677

DO - 10.11250/chemotherapy1953.36.Supplement5_677

M3 - Article

AN - SCOPUS:0023696995

VL - 36

SP - 677

EP - 690

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3165

ER -

Cefodizime in complicated urinary tract infections

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this